Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2016 - 2025)

Ocular Therapeutix has reported Non-Current Deffered Revenue over the past 12 years, most recently at $14.0 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $14.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $14.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $14.0 million, changed 0.0%.
  • Non-Current Deffered Revenue for Q4 2025 was $14.0 million at Ocular Therapeutix, roughly flat from $14.0 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for OCUL hit a ceiling of $14.3 million in Q2 2023 and a floor of $12.0 million in Q1 2021.
  • Median Non-Current Deffered Revenue over the past 5 years was $14.0 million (2024), compared with a mean of $13.5 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: increased 12.78% in 2022 and later decreased 1.78% in 2024.
  • Ocular Therapeutix's Non-Current Deffered Revenue stood at $13.0 million in 2021, then rose by 2.98% to $13.4 million in 2022, then increased by 5.59% to $14.1 million in 2023, then dropped by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $14.0 million (Q4 2025), $14.0 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.